tirzepatide cardiovascular outcomes trial results august 2025 Superior Cerebrovascular with versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients | Drugs and Therapy Cardiovascular Outcomes in Adults With

Evaluation of glucagon-like peptide-1 receptor expression in non-diabetic and diabetic atherosclerotic mice using PET tracer (68)Ga-NODAGA-exendin-4

Ebselen and structurally related compounds may exert their therapeutic effects, at least in part, through NOX inhibition

For women who have central [abdominal] obesity and are starting to show markers of other diseases, these medications can assist in optimising their metabolic health, Katherine explains

Liberacet is a GLP-1 receptor agonist that mimics the effects of human GLP-1 , selectively binds to the GLP-1 receptor, increases cAMP release, promotes insulin secretion, inhibits glucagon secretion, and thus lowers blood sugar levels